NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND ANTICANCER POTENTIAL OF SANTHEMOIDIN
International Journal of Drug Delivery Technology · 08.06.2026 · 16 (48s)
DOI: 10.25258/ijddt.16.48s.100 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 08.06.2026. Verfasst von Abhishek Jayswal und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Breast cancer is one of the most prevalent malignancies worldwide, with increasing incidence, high mortality, and significant therapeutic challenges due to tumor heterogeneity, metastasis, and multidrug resistance. Santhemoidin A, a naturally occurring sesquiterpene lactone isolated from medicinal plants of the Asteraceae family, has shown promising biological activities; however, its anticancer potential against breast cancer remains largely unexplored. The present study aimed to investigate the molecular mechanisms and therapeutic potential of Santhemoidin A against breast cancer using an integrated network pharmacology, molecular docking, and ADMET approach. A total of 108 Santhemoidin A-associated protein targets were identified through SwissTargetPrediction and Similarity Ensemble Approach databases. These were intersected with 152,609 breast cancer-related genes retrieved from the GeneCards database, resulting in 108 common targets. Protein–protein interaction analysis identified key hub genes including APP, MMP9, AGTR1, MMP2, MAPK8, PARP1, ADAM17, CTSS, MDM2, and KDR, indicating their potential roles in the anticancer effects of Santhemoidin A. Gene Ontology enrichment revealed significant involvement in biological processes associated with inflammation, extracellular matrix remodeling, apoptosis, and cellular signaling. KEGG pathway analysis highlighted several critical cancer-related pathways, including MAPK signaling, Ras signaling, Notch signaling, calcium signaling, sphingolipid signaling, and pathways in cancer. ADMET analysis demonstrated favorable drug-likeness, high gastrointestinal absorption, acceptable oral bioavailability, and low predicted toxicity, supporting its pharmacokinetic suitability. Molecular docking studies revealed strong and stable binding interactions of Santhemoidin A with multiple therapeutic targets, with PARP1 showing the highest binding affinity (−10.0 kcal/mol), followed by CTSS (−8.4 kcal/mol), KDR (−8.3 kcal/mol), and MMP2 (−8.0 kcal/mol). These interactions were supported by hydrogen bonding, hydrophobic contacts, and electrostatic interactions within the active sites of target proteins. Overall, the findings suggest that Santhemoidin A exerts potential multi-target anticancer effects against breast cancer through modulation of key signaling pathways involved in tumor progression, apoptosis, angiogenesis, and metastasis, highlighting its promise as a natural therapeutic candidate for breast cancer management.
Zitieren
APA
Jayswal, A., & Waghmare, A. (2026). NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND ANTICANCER POTENTIAL OF SANTHEMOIDIN. International Journal of Drug Delivery Technology, 16(48s). https://doi.org/10.25258/ijddt.16.48s.100
Vancouver
Jayswal A, Waghmare A. NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND ANTICANCER POTENTIAL OF SANTHEMOIDIN. International Journal of Drug Delivery Technology. 2026;16(48s). doi:10.25258/ijddt.16.48s.100
BibTeX
@article{Jayswal2026,
author = {Jayswal, Abhishek and Waghmare, Atish},
title = {NETWORK PHARMACOLOGY, MOLECULAR DOCKING AND ANTICANCER POTENTIAL OF SANTHEMOIDIN},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {48s},
doi = {10.25258/ijddt.16.48s.100}
}
EUVIMED